Literature DB >> 23247102

A molecular imaging system based on both transcriptional and genomic amplification to detect prostate cancer cells in vivo.

Frédéric Pouliot1, Makoto Sato, Ziyue Karen Jiang, Steve Huyn, Breanne Dw Karanikolas, Lily Wu.   

Abstract

An imaging modality that can accurately discern prostate cancer (PCa) foci would be useful to detect PCa early or guide treatment. We have engineered numerous adenoviral vectors (Ads) to carry out reporter gene-based imaging using specific promoters to express a potent transcriptional activator, which in turn activates the reporter gene in PCa. This two-step transcriptional amplification (TSTA) method can boost promoters' activity, while maintaining cell specificity. Here, we examined a dual TSTA (DTSTA) approach, which utilizes TSTA not only to express the imaging reporter, but also to direct viral genome replication of a conditionally replicating Ad (CRAd) to further augment the expression levels of the reporter gene by genomic amplification supported in trans by coadministered CRAd. In vitro studies showed up to 50-fold increase of the reporter genome by DTSTA. Compared with TSTA reporter alone, DTSTA application exhibited a 25-fold increase in imaging signal in PCa xenografts. DTSTA approach is also beneficial for a combination of two TSTA Ads with distinct promoters, although amplification is observed only when TSTA-CRAd can replicate. Consequently, the DTSTA approach is a hybrid method of transcriptional and genomic augmentation that can provide higher level reporter gene expression potentially with a lower dose of viral administration.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23247102      PMCID: PMC3589161          DOI: 10.1038/mt.2012.259

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  32 in total

1.  Molecular engineering of a two-step transcription amplification (TSTA) system for transgene delivery in prostate cancer.

Authors:  Liqun Zhang; Jason Yeates Adams; Erika Billick; Romyla Ilagan; Meera Iyer; Kim Le; Andrea Smallwood; Sanjiv S Gambhir; Michael Carey; Lily Wu
Journal:  Mol Ther       Date:  2002-03       Impact factor: 11.454

2.  Augmenting transgene expression from carcinoembryonic antigen (CEA) promoter via a GAL4 gene regulatory system.

Authors:  P E Koch; Z S Guo; S Kagawa; J Gu; J A Roth; B Fang
Journal:  Mol Ther       Date:  2001-03       Impact factor: 11.454

3.  Indirect imaging of cardiac-specific transgene expression using a bidirectional two-step transcriptional amplification strategy.

Authors:  I Y Chen; O Gheysens; S Ray; Q Wang; P Padmanabhan; R Paulmurugan; A M Loening; M Rodriguez-Porcel; J K Willmann; A Y Sheikh; C H Nielsen; G Hoyt; C H Contag; R C Robbins; S Biswal; J C Wu; S S Gambhir
Journal:  Gene Ther       Date:  2010-03-18       Impact factor: 5.250

4.  In vivo imaging of intraprostatic-specific gene transcription by PET.

Authors:  Frédéric Pouliot; Breanne D W Karanikolas; Mai Johnson; Makoto Sato; Saul J Priceman; David Stout; Joanne Sohn; Nagichettiar Satyamurthy; Jean B deKernion; Lily Wu
Journal:  J Nucl Med       Date:  2011-04-15       Impact factor: 10.057

5.  Two-step transcriptional amplification as a method for imaging reporter gene expression using weak promoters.

Authors:  M Iyer; L Wu; M Carey; Y Wang; A Smallwood; S S Gambhir
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-04       Impact factor: 11.205

6.  Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectors.

Authors:  L Wu; J Matherly; A Smallwood; J Y Adams; E Billick; A Belldegrun; M Carey
Journal:  Gene Ther       Date:  2001-09       Impact factor: 5.250

7.  Tumor-specific transcriptional targeting of suicide gene therapy.

Authors:  J Qiao; M Doubrovin; B V Sauter; Y Huang; Z S Guo; J Balatoni; T Akhurst; R G Blasberg; J G Tjuvajev; S-H Chen; S L C Woo
Journal:  Gene Ther       Date:  2002-02       Impact factor: 5.250

8.  Amplified Muc1-specific gene expression in colon cancer cells utilizing a binary system in adenoviral vectors.

Authors:  Andreas Block; Dragan Milasinovic; Juergen Mueller; Peter Schaefer; Hansjoerg Schaefer; Heiner Greten
Journal:  Anticancer Res       Date:  2002 Nov-Dec       Impact factor: 2.480

9.  Visualization of advanced human prostate cancer lesions in living mice by a targeted gene transfer vector and optical imaging.

Authors:  Jason Y Adams; Mai Johnson; Makoto Sato; Frank Berger; Sanjiv S Gambhir; Michael Carey; M Luisa Iruela-Arispe; Lily Wu
Journal:  Nat Med       Date:  2002-07-22       Impact factor: 53.440

10.  Interrogating androgen receptor function in recurrent prostate cancer.

Authors:  Liqun Zhang; Mai Johnson; Kim H Le; Makoto Sato; Romyla Ilagan; Meera Iyer; Sanjiv S Gambhir; Lily Wu; Michael Carey
Journal:  Cancer Res       Date:  2003-08-01       Impact factor: 12.701

View more
  4 in total

Review 1.  Molecular-genetic imaging of cancer.

Authors:  Il Minn; Mitchell E Menezes; Siddik Sarkar; Keerthi Yarlagadda; Swadesh K Das; Luni Emdad; Devanand Sarkar; Paul B Fisher; Martin G Pomper
Journal:  Adv Cancer Res       Date:  2014       Impact factor: 6.242

2.  Investigation of the In Vitro and In Vivo efficiency of RM-532-105, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, in LAPC-4 prostate cancer cell and tumor models.

Authors:  Lucie Carolle Kenmogne; Jenny Roy; René Maltais; Mélanie Rouleau; Bertrand Neveu; Frédéric Pouliot; Donald Poirier
Journal:  PLoS One       Date:  2017-02-09       Impact factor: 3.240

3.  A PCA3 gene-based transcriptional amplification system targeting primary prostate cancer.

Authors:  Bertrand Neveu; Pallavi Jain; Bernard Têtu; Lily Wu; Yves Fradet; Frédéric Pouliot
Journal:  Oncotarget       Date:  2016-01-12

4.  Bioluminescence Microscopy as a Method to Measure Single Cell Androgen Receptor Activity Heterogeneous Responses to Antiandrogens.

Authors:  Pallavi Jain; Bertrand Neveu; Lauriane Velot; Lily Wu; Yves Fradet; Frédéric Pouliot
Journal:  Sci Rep       Date:  2016-09-28       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.